Enlivex Therapeutics is trading at $2.05 (5.1% up) in pre-market as investors reassess the stock following a sharp two-day selloff triggered by a surprise $400 million private placement.
- The stock plummeted over 47% on July 28 and another 12-13% on July 30 after announcing a crypto-funded deal with a single investor, which sparked major dilution concerns.
- Today’s modest rebound aligns with broader market gains and a potential stabilization as the market processes the impact of the massive capital raise.